Gonorrhea (GN): Competitive Landscape

This reports provides a data-driven overview of the current and future competitive landscape in Gonorrhea therapeutics.

In 2024, more than 3.7 million diagnosed incident cases of GN are anticipated in the 16 countries covered in the analyst’s epidemiology forecast.
Currently, the GN market contains many innovative therapies developed by big pharma giants.
R&D efforts for GN are limited. Currently, 33 molecules are in the pipeline, with none in Phase I trials or the pre-registration stage.
Over the past 10 years, 344 clinical trials have been conducted for N. gonorrhoeae infections. The highest number of studies was conducted in 2018 (75 trials).
During the past decade, acquisitions were the most prevalent deal type in North America, Europe, Asia-Pacific, and South and Central America.

Scope

The Gonorrhea: Competitive Landscape combines data from the Pharma Intelligence Center with in-house analyst expertise to provide a competitive assessment of the disease marketplace.

Components of the report include:

• Disease Landscape
• Disease Overview
• Epidemiology Overview
• Treatment Overview
• Marketed Products Assessment
• Breakdown by Mechanism of Action, Route of Administration
• Product Profiles with Sales Forecast
• Pricing and Reimbursement Assessment
• Annual Therapy Cost
• Time to Pricing and Time to Reimbursement
• Pipeline Assessment
• Breakdown by Development Stage, Mechanism of Action, Molecule Type, Route of Administration
• Product Profiles with Sales Forecast
• Late-to-mid-stage Pipeline Drugs
• Phase Transition Success Rate and Likelihood of Approval
• Clinical Trials Assessment
• Breakdown of Trials by Phase, Status, Virtual Components, Sponsors, Geography, and Endpoint Status
• Enrolment Analytics, Site Analytics, Feasibility Analysis
• Deals Landscape
• Mergers, Acquisitions, and Strategic Alliances by Region
• Overview of Recent Deals
• Commercial Assessment
• Key Market Players
• Future Market Catalysts

Reasons to Buy

• Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
• Develop business strategies by understanding the trends shaping and driving the Gonorrhea market.
• Drive revenues by understanding the key trends, innovative products and technologies, and companies likely to impact the global Gonorrhea market in the future.
• Formulate effective sales and marketing strategies by understanding the competitive landscape and analyzing the performance of various competitors.
• Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
• Organize your sales and marketing efforts by identifying the market categories that present the maximum opportunities for consolidations, investments, and strategic partnerships.